Trial Profile
Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Carcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 06 Dec 2020 Results assessing comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer, published in the European Journal of Cancer
- 15 Sep 2020 Status changed from active, no longer recruiting to completed.
- 31 Jul 2020 Planned End Date changed from 31 Dec 2020 to 30 Sep 2020.